23andMe, founded in April 2006 by Linda Avey, Paul Cusenza, and Anne Wojcicki. The company has not officially endorsed a plan to participate in an IPO.

23andMe provides at-home, consumer genetic testing and was the first FDA-approved direct-to-consumer genetic sequencing supplier. More recently, 23andMe has leveraged its genetic database in pursuit of pharmaceutical drug development. The company has raised nearly $800 million in Venture Capital funding from investors including GlaxoSmithKline, Pegasus Tech Ventures, MicroVentures, G Squared, Sapphire Ventures, Sequoia Capital, SharesPost, Fidelity, GV, and Genetech. It has been widely reported that 23andMe last raised $300 million in July 2018 at a post-money valuation of $2.5 billion.

Register for Details

For more details on financing and valuation for 23andMe, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about 23andMe

Forge green plus iconForge green minus icon

What is 23andMe's IPO price?

23andMe's IPO price is $0.67 as of 1/18/24.
Forge green plus iconForge green minus icon

What is 23andMe's funding to date?

23andMe has raised $876.61MM to date.
Forge green plus iconForge green minus icon

When was 23andMe founded?

23andMe was founded in 2006.

Who are 23andMe's major investors?

Fidelity Investments
Casdin Capital
Altimeter Capital

23andMe Funding Rounds and Last Known Valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
12/23/2020 Series F-1 $385MM raised $XXX.XX $XXX.XX
9/12/2017 Series F $250MM raised $XXX.XX $XXX.XX
6/8/2015 Series E $115.25MM raised $XXX.XX $XXX.XX
12/10/2012 Series D $58.45MM raised $XXX.XX $XXX.XX
11/10/2010 Series C $31.18MM raised $XXX.XX $XXX.XX
12/23/2009 Series B $27.78MM raised $XXX.XX $XXX.XX
5/22/2007 Series A $8.95MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: May 22, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.